Abstracts tagged "fibromyalgia"

Abstract Number: 2055 • 2014 ACR/ARHP Annual Meeting
Are There Immunological Abnormalities in Fibromyalgia Patients: Flow Cytometry Analysis
Robert S. Katz¹, Hannah Bond² and Daniel Pickrell², ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: Fibromyalgia is not thought to have an immunological pathogenesis: However, few studies have been done to evaluate immunological abnormalities. We analyzed lymphocyte subsets in…
Abstract Number: 401 • 2014 ACR/ARHP Annual Meeting
Association of Anti-Thyroid Autoantibodies with Fibromyalgia in Rheumatoid Arthritis
Jowairiyya Ahmad¹, Helena Blumen², Claudene George³, Asha Shrestha⁴ and Clement Tagoe⁵, ¹Geriatrics, Albert Einstein College of Medicine/Montefiore Medical Centre, Bronx, NY, ²Geriatrics, Albert Einstein College of Medicine, Bronx, NY, ³Geriatrics, Albert Einstein College of Medicine/Montefiore Medical centre, Bronx, NY, ⁴Rheumatology, Albert Einstein College of Medicine/Montefiore Medical Centre, Bronx, NY, ⁵Rheumatology, Albert Einsetin College of Medicine/Montefiore Medical Centre, Bronx, NY
Background/Purpose Autoimmune thyroiditis has been linked independently with fibromyalgia and chronic widespread pain. We studied how the presence of autoimmune thyroiditis affects the clinical presentation…
Abstract Number: 1879 • 2014 ACR/ARHP Annual Meeting
The Efficacy of Pregabalin for Treating Fibromyalgia Patients with Moderate or Severe Baseline Widespread Pain
Andrew Clair and Birol Emir, Pfizer Inc, New York, NY
Background/Purpose: Pregabalin has demonstrated efficacy for the treatment of fibromyalgia (FM), but insufficient evidence exists on how the efficacy of pregabalin may differ by baseline…
Abstract Number: 252 • 2014 ACR/ARHP Annual Meeting
Preliminary Validation of the Michigan Body Map
Chad M. Brummett¹, Jenna Goesling², Rishi Bakshi³, Jennifer Wolfe⁴, Stephanie Moser⁵, David A. Williams⁶ and Afton L. Hassett⁷, ¹Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, ²Department of Anesthesiology, University of Michigan Health System, Ann Arbor, MI, ³Physical Medicine and Rehabilitation, University of Michigan Medical School, Ann Arbor, MI, ⁴Anesthesiology, University of Michigan Health System, Ann Arbor, MI, ⁵Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, ⁶Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI, ⁷Anesthesiology, University of Michigan, Ann Arbor, MI
Background/Purpose One of the hallmark features of fibromyalgia and other centralized pain states is widespread body pain. We developed the Michigan Body Map (MBM) to…
Abstract Number: 842 • 2013 ACR/ARHP Annual Meeting
A Cytokine/Chemokine Multiplex Assay That Is Sensitive and Specific For Fibromyalgia Compared To Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis
Daniel J. Wallace¹, Igor Gavin², Oleksiy Karpenko² and Bruce S. Gillis³, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Illinois College of Medicine at Chicago, Chicago, IL, ³Department of Pathology, University of Illinois College of Medicine at Chicago, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a chronic pain and fatigue syndrome that affects about 6 million adults in the United States. The clinical diagnosis of…
Abstract Number: 2849 • 2013 ACR/ARHP Annual Meeting
Medication Adherence and Healthcare Costs Among Patients With Fibromyalgia: Combination Medication Versus Duloxetine, Pregabalin, and Milnacipran Initiators
Nicole Marlow¹, Kit Simpson², James Zoller² and E. Baron Short³, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Healthcare Leadership and Management, Medical University of South Carolina, Charleston, SC, ³Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
Background/Purpose: The combined use of prescription drugs (Rx) with complementary mechanisms of action has been described for treating fibromyalgia (FM). We examined medication adherence and…
Abstract Number: 2850 • 2013 ACR/ARHP Annual Meeting
Once Daily Controlled-Release Pregabalin In Fibromyalgia Patients: A Phase 3 Double-Blind, Randomized Withdrawal, Placebo-Controlled Study
Lesley M. Arnold¹, Pierre Arsenault², Cynthia Huffman³, Jeffrey L. Patrick⁴, Michael Messig⁴, Marci L. Chew⁴, Luis Sanin⁴, Lynne Pauer⁴ and Andrew Clair⁴, ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Département de Médecine de Famille, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Meridien Research, Tampa, FL, ⁴Pfizer Inc, New York, NY
Background/Purpose: Pregabalin (PGB) is currently approved for the treatment of fibromyalgia (FM) for twice daily dosing over a range of 300-450 mg/day. A pregabalin controlled-release…
Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting
Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia
John S. Sampalis^1,2, Mary-Ann Fitzcharles³, Peter A. Ste-Marie⁴, Emmanouil Rampakakis^1,2 and Yoram Shir⁴, ¹JSS Medical Research, Montreal, QC, Canada, ²Jewish General Hospital, McGill University, Montreal, QC, Canada, ³Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…
Abstract Number: 2092 • 2013 ACR/ARHP Annual Meeting
Strengthening Exercises Using A Swiss Ball Improve Symptoms and Muscle Performance Of Patients With Fibromyalgia: A Randomized Controlled Study
Josiander Arakaki Sr., RHEUMATOLOGY, UNIFESP, sao paulo, Brazil
Background/Purpose: Fibromyalgia (FM) is a disorder characterized by chronic widespread pain, fatigue and reduced muscle strength. Exercise is fundamental to the treatment of FM and…
Abstract Number: 1948 • 2013 ACR/ARHP Annual Meeting
Power Doppler Ultrasound 7-Joint Score Vs. Simplified Disease Activity Index In Rheumatoid Arthritis Associated With Fibromyalgia
Rafael Chakr¹, Marina Behar², José A. Mendonça³, Daniela Cervantes², Nizele Calegaro², Nicole Andrade², Iuri Siqueira², Daniel Zanchet², Andrese Gasparin², Penélope Esther Palominos², Charles Kohem⁴, Odirlei Andre Monticielo⁵, Claiton Brenol⁶, Ricardo M. Xavier² and João Carlos T. Brenol⁷, ¹Rheumatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Rheumatology, Pontifical Catholic University of Campinas / Institute of Clinical Research – IPECC, Campinas, Brazil, ⁴Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, ⁵Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁷Rheumatology Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: Fibromyalgia (FM) falsely increases rheumatoid arthritis (RA) disease activity clinical composite scores, such as the simplified disease activity index (SDAI), recently incorporated into ACR/EULAR…
Abstract Number: 140 • 2013 ACR/ARHP Annual Meeting
Fibromyalgia and Pregnancy: Challenges Of The Savella^® (Milnacipran) Pregnancy Registry
Damien Hirsch¹, Denise Leclair¹, Robert H. Palmer¹, Vikki Brown², Susan Sinclair Roberts^2,3 and Janice McLean², ¹Forest Research Institute, Inc., Jersey City, NJ, ²INC Research, LLC, Wilmington, NC, ³University of North Carolina Wilmington, Wilmington, NC
Background/Purpose: During pregnancy, women with fibromyalgia (FM) often experience worsening of symptoms, which include widespread pain, fatigue, sleep disturbances, cognitive difficulties, and reduced daily functioning.…
Abstract Number: 1101 • 2013 ACR/ARHP Annual Meeting
Neuromuscular Taping On Patients With Fibromyalgia May Be a Useful Tool To Relief Muscular Pain
Camillo Giacomelli, Antonino Santagati, Arianna Consensi, Alessandra Rossi, Stefano Bombardieri and Laura Bazzichi, University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Fibromyalgia (FMS) is an illness characterized by an anomalous perception of the painful stimuli that are supposed to be attributable to a combination of…
Abstract Number: 142 • 2013 ACR/ARHP Annual Meeting
Home Tender Point Measurement In Fibromyalgia Patients
Robert S. Katz¹, Hannah Bond² and Jessica L. Polyak², ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: To determine whether: 1) patients with the fibromyalgia syndrome (FMS) can accurately evaluate their own tender points, similar to self-administered testing for other purposes…
Abstract Number: 1094 • 2013 ACR/ARHP Annual Meeting
Hyperbaric Oxygen Ameliorates Fibromyalgia Symptoms and Functional Impairment – A Randomized Prospective Trial
Shai Efrati¹, Jacob N. Ablin², Yair Bechor³, Shir Daphna-Tekoah⁴, Gregory Fishlev⁵, Yifat Faran⁴, Jacob Bergan⁶, Mony Friedman⁶ and Dan Buskila⁷, ¹Research & Development Unit and Hyperbaric institute, Asaf-Harofeh medical center, Beer Yaacov, Zerifin, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Institute of Hyperbaric Medicine, Asaf-Harofeh medical center, Beer Yaacov, Zerifin, Israel, ⁴School of Social Work, Ashkelon Academic College, Ashkelon, Israel, ⁵Institute of Hyperbaric Medicine, Assaf Harofeh Medical Center, Beer Yaacov, Zerifin, Israel, ⁶Hyperbaric institute, Asaf-Harofeh medical center, Beer Yaacov, Zerifin, Israel, ⁷Ben-Gurion University, Beer-Sheva, Israel
Background/Purpose: Fibromyalgia Syndrome (FMS), considered to represent a prototype of central nervous system sensitization, is a common condition characterized by chronic widespread pain and diffuse…
Abstract Number: 143 • 2013 ACR/ARHP Annual Meeting
Rapid Infrared Microscopy (IRMS) For Differential Diagnosis Of Fibromyalgia and Other Central Sensitivity Syndromes
Kevin V. Hackshaw¹, Luis Rodriguez-Saona², Irving L. Rosenberg³, Marcal Plans² and C.A. Tony Buffington⁴, ¹Immunology/Rheumatology, The Ohio State University, Columbus, OH, ²Food Sciences, The Ohio State University, Columbus, OH, ³Immunology/ Rheumatology, The Ohio State University, Columbus, OH, ⁴Veterinary Biological Sciences, The Ohio State University, Columbus, OH
Background/Purpose: Background/Purpose: The aim of this study was to investigate the ability of a rapid blood-spot-based method for diagnosis of Fibromyalgia (FM) using mid-infrared microspectroscopy (IRMS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].